Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

COSCIENS Biopharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(109)
•••
Post by prophetoffactzon Jun 29, 2024 11:17pm
223 Views
Post# 36112456

Top-line diagnostic results

Top-line diagnostic resultsAEZS's pediatric clinical trial completed its last patient last visit 16 days ago with top-line results expected in Q3 2024. 

AEZS's adult clinical trial was completed 2016-11-29 according to clinicaltrials.gov: Study Details | Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency | ClinicalTrials.gov

Top-line results for the adult trial were reported 36 days later in a news release: 2017-01-04 | Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™ | TSX:AEZS | Press Release (stockhouse.com)

The 36 days to report the top-line adult clinical trial results may have been complicated by Christmas and New Year's holidays.

Assuming it takes 30-36 days to report the pediatric top-line results, given that it has been 16 days since the last patient last visit, it may be possible that we see the top-line results for the pediatric trial in 2-3 weeks. That puts it potentially right around the time of the AGM on July 16, 2024.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities